Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:34 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 10,818 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Completed No phase listed Observational

Developmental Phenomenology of Obsessive Compulsive Disorder and Tourette Syndrome in Children and Adolescents

NCT00004324
View directory record Official record
Conditions
Tourette Syndrome, Obsessive Compulsive Disorder
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1989
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 5:34 PM EST
Enrolling by invitation Not applicable Interventional

Ready, Set, Go! A Physical Fitness Intervention for Children With Mobility Challenges

NCT04789746
View directory record Official record
Conditions
Cerebral Palsy, Myelomeningocele, Arthrogryposis, Motor Skills Disorders, Gross Motor Development Delay
Interventions
adapted Chicago Run running program
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
6 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Chicago Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 2, 2026, 5:34 PM EST
Completed Not applicable Interventional

Comparison of Scar Formation in Syndactyly Release Surgery With Full Thickness Skin Graft Versus Skin Graft Substitute

NCT03107546
View directory record Official record
Conditions
Syndactyly
Interventions
Hyalomatrix, Skin graft
Device · Other
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
Up to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Nov 2, 2026, 5:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Peer-led Social Media Intervention to Prevent HIV Among Young Men Who Have Sex With Men (YMSM)

NCT04417946
View directory record Official record
Conditions
Pre-Exposure Prophylaxis, Hiv, Men
Interventions
PrEP messages, Heath messages
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Nov 2, 2026, 5:34 PM EST
Completed Not applicable Interventional Results available

Urological and Renal Disease Engaging Adolescents in Adherence Collaborative Trial

NCT03045276
View directory record Official record
Conditions
Spina Bifida, Kidney Transplant
Interventions
Behavioral Feedback and Economic Incentives: Arm 1, Behavioral Feedback and Economic Incentives: Arm 2
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years to 24 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Nov 2, 2026, 5:34 PM EST
Terminated No phase listed Observational

Natural History Study of Children With Metachromatic Leukodystrophy

NCT01963650
View directory record Official record
Conditions
Lipid Metabolism Disorders, Metachromatic Leukodystrophy (MLD), Nervous System Diseases, Brain Diseases, Central Nervous System Diseases, Demyelinating Diseases, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Sphingolipidoses, Hereditary Central Nervous System Demyelinating Diseases, Metabolic Inborn Brain Diseases, Lysosomal Storage Diseases, Metabolic Diseases, Sulfatidosis
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
Up to 12 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Torrance, California • Washington D.C., District of Columbia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Nov 2, 2026, 5:34 PM EST
Recruiting Not applicable Interventional

Early Feeds in Gastroschisis

NCT06878950
View directory record Official record
Conditions
Gastroschisis
Interventions
Early Feeding Protocol
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
0 Days to 1 Year
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 2, 2026, 5:34 PM EST
Completed Phase 2 Interventional

A Study in Pediatric Patients With Cystic Fibrosis Lung Disease

NCT00130182
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
denufosol tetrasodium (INS37217)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
5 Years to 7 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Denver, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Nov 2, 2026, 5:34 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

NCT04990388
View directory record Official record
Conditions
Glycogen Storage Disease Type III
Interventions
UX053, Placebo, Antipyretic, H2 Blocker, H1 Blocker
Biological · Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Nov 2, 2026, 5:34 PM EST
Completed Phase 2 Interventional Results available

Pharmacokinetics of Linezolid in Children With Cystic Fibrosis

NCT00625703
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Linezolid
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Nov 2, 2026, 5:34 PM EST
Completed Phase 1 Interventional Results available

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

NCT02093923
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Nov 2, 2026, 5:34 PM EST
Completed No phase listed Observational

Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation

NCT05190679
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
None/Observational Studies
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years and older
Enrollment
155 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 2, 2026, 5:34 PM EST
Completed Not applicable Interventional

Ultrasound Acute Chest Syndrome Sickle Cell Disease

NCT06880679
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Point of Care Ultrasound
Device
Lead sponsor
Indiana University
Other
Eligibility
Up to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 2, 2026, 5:34 PM EST
Completed Not applicable Interventional

Preparing Heart and Mind™: A Patient Engagement Pathway for Parents and Their Caregiving Partners After a Major Fetal Anomaly Diagnosis

NCT05282368
View directory record Official record
Conditions
Parent Mental Health
Interventions
PHM™ Pathway
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Nov 2, 2026, 5:34 PM EST
Recruiting Not applicable Interventional

Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study

NCT07114718
View directory record Official record
Conditions
Congenital Heart Disease, Congenital Heart Disease (CHD)
Interventions
Ductus Arteriosus Stent
Device
Lead sponsor
Starlight Cardiovascular Inc
Industry
Eligibility
1 Minute to 6 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 2, 2026, 5:34 PM EST
Completed Phase 1 Interventional

PEG-Glucocerebrosidase for the Treatment of Gaucher Disease

NCT00001410
View directory record Official record
Conditions
Gaucher's Disease
Interventions
Lysodase
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 2, 2026, 5:34 PM EST
Completed No phase listed Observational

Genetic Studies in the Amish and Mennonites

NCT00359580
View directory record Official record
Conditions
Genetic Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
Bethesda, Maryland • Strasburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 2, 2026, 5:34 PM EST
Completed Phase 2 Interventional Results available

Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients

NCT01975935
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Amlexanox, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Nov 2, 2026, 5:34 PM EST
Completed Phase 2 Interventional

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

NCT00838708
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
SRD174 Cream, vehicle cream
Drug · Other
Lead sponsor
Serentis Ltd.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Oceanside, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2009 · Synced Nov 2, 2026, 5:34 PM EST
Recruiting Not applicable Interventional

Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

NCT07454174
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Ren-Nu and KetoCitra
Dietary Supplement
Lead sponsor
Richard Fatica
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 2, 2026, 5:34 PM EST
Completed No phase listed Observational

MRI QSM Imaging for Iron Overload

NCT04631718
View directory record Official record
Conditions
Hemochromatosis, Iron Overload
Interventions
Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
5 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Stanford, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Nov 2, 2026, 5:34 PM EST
Active, not recruiting No phase listed Observational

A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

NCT04848779
View directory record Official record
Conditions
Glycogen Storage Disease Type II
Interventions
Alglucosidase alfa GZ419829
Drug
Lead sponsor
Sanofi
Industry
Eligibility
0 Days to 6 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Hawthorne, New York • Durham, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 2, 2026, 5:34 PM EST
Completed Phase 2Phase 3 Interventional

Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency

NCT00460096
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Kamada-API
Drug
Lead sponsor
Kamada, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Denver, Colorado • Gainesville, Florida • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2007 · Synced Nov 2, 2026, 5:34 PM EST
Completed Not applicable Interventional

Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1

NCT05377008
View directory record Official record
Conditions
Neurocognitive Deficit, Mental Health Impairment, Neurofibromatosis 1
Interventions
OPTIMAL-SSI
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years to 16 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Nov 2, 2026, 5:34 PM EST